JAGX
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea.
Jaguar Animal Health Inc (JAGX) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Revisions (C-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-05 | C+ (2.7) | C (2.3) | B (3.3) | C (2.4) | C- (1.9) | C+ (2.5) |
| 2026-08-04 | C+ (2.7) | C (2.3) | B (3.3) | C (2.4) | C- (1.9) | C+ (2.5) |
| 2026-08-03 | C+ (2.7) | C (2.4) | B (3.2) | C (2.4) | C- (2.0) | C+ (2.5) |
| 2026-08-02 | C+ (2.7) | C (2.4) | B- (3.1) | C (2.4) | C- (1.9) | C+ (2.5) |
| 2026-07-29 | C+ (2.6) | B+ (3.6) | C+ (2.6) | F (0.2) | D+ (1.5) | C- (2.1) |